Manufacturing Wire

MISUMI Americas released a reshoring report and is supporting a manufacturing training bill.

TSMC is expanding its U.S. semiconductor investment to US$165 billion, with the headline tying the move to AI growth.

Bosch has secured up to $225 million in CHIPS funding tied to a $2 billion semiconductor expansion in Roseville.

TSMC announced another $100 billion expansion of its U.S. chip manufacturing footprint.

The headline reports that TSMC has pledged $100bn to expand its Arizona chip facility while profits are rising.

Taiwanese chipmaker TSMC has pledged another $100 billion to expand chipmaking capacity in the United States.

A Parsec survey reports that 72% of manufacturers have adopted AI, while only 10% have implemented it at scale.

The headline frames a Q&A on what would be required to reshore drug manufacturing in the United States.

The headline reports that Taiwan suppliers are being pushed toward U.S. manufacturing expansion by the AI infrastructure boom.

Bosch has secured $225 million in CHIPS funding for a semiconductor expansion in Roseville.

The headline reports that Bosch has begun sample production at its first U.S. semiconductor plant.

The headline says U.S.-made chips are seeing a comeback and frames the development as relevant for investors.

The U.S. Commerce Secretary is urging Samsung and SK Hynix to expand semiconductor fabs in the United States.

Micron announced a strategic investment of up to $3 billion to strengthen the U.S. semiconductor ecosystem.

The headline reports that Comfort Systems USA is being highlighted as the lead name among three stock picks tied to the U.S. reshoring boom.

The headline reports an FAQ-style look at the status of U.S. pharmaceutical reshoring in 2026.

The headline reports a Q&A with Ryan Last on reshoring pharma and biotech manufacturing ahead of tariff deadlines this summer.

The headline frames American enterprise across a 250-year history and argues that its best work remains ahead.

Douglas Brown’s The Black Book of Reshoring was named a finalist in the Business category of the 2026 International Book Awards.

The headline reports on realistic timelines for reshoring pharmaceutical manufacturing.